Event
Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026
Monday, January 12, 2026
Event Details
DateMonday, January 12, 2026
11:30 a.m. - 2:30 p.m. PT
For questions, please contact sfevents@sidley.com.
Join members of Sidley's Global Life Sciences team for a lunchtime CLE-accredited program during the JPM Healthcare Conference discussing the latest regulatory trends impacting the next wave of development-stage transactions.
Led by Meena Datta, global co-leader of Sidley's Healthcare practice; Torrey Cope, partner in Sidley's Food Drug and Medical Device (FDMD) practice; and Sally Wagner Partin, partner in Sidley's M&A practice, this session provides keen insights on the considerations driving recent biotech dealmaking. 1 hour CLE credit available.
Contacts
Offices
Related Resources
Capabilities
Suggested News & Insights
Sidley Sponsors the 2026 EU Pharma Law ForumTuesday, May 19, 2026 – Thursday, May 21, 2026Inside Strategic Partnerships: Clinical Trial Considerations and AI/Digital Health InsightsThursday, March 12, 2026Generative AI and Privilege: Practical Lessons from Two Early Decisions and What Comes NextFebruary 27, 2026Sidley Represents Precision NeuroMed in Its Strategic Partnership With Brainlab SEFebruary 27, 2026TX AG’s Office Continues Aggressive Enforcement Against Healthcare Entities Operating in TexasFebruary 25, 2026New York LLC Transparency Act Took Effect January 1, 2026; U.S.-Formed LLCs Exempt from Reporting ObligationsFebruary 25, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory